The Respiratory Syncytial Virus Market Size in the 7MM was observed to be ~USD 1,200 million in 2022 | Major Companies- Bavarian Nordic, GlaxoSmithKline, Janssen, Sanofi, AstraZeneca, Moderna, ReViral, Pfizer, and Others

The Respiratory Syncytial Virus market report provides current treatment practices, Respiratory Syncytial Virus emerging drugs, Respiratory Syncytial Virus market share of individual therapies, and current and forecasted epidemiology in 7MM covering the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

The Respiratory Syncytial Virus Market research report conducts a careful market evaluation and provides a professional analysis of the industry taking into account market development, present market circumstances, and forecasts for the future. The Respiratory Syncytial Virus market driving factors, market overview, industry volume, and market share are also highlighted in this Respiratory Syncytial Virus Market report analysis.

Key Takeaways from the Respiratory Syncytial Virus Market Report

• In 2022, the total incident cases of Respiratory Syncytial Virus in the 7MM were ~8,495,000, and these cases are anticipated to increase during the study period.

• In 2022, as per the severity of Respiratory Syncytial Virus infection in children, mild, moderate, and severe cases formed 70%, 27%, and 3% of the total incident cases of Respiratory Syncytial Virus in the US, respectively.

• The market size of the Respiratory Syncytial Virus in the 7MM was observed to be ~USD 1,200 million in 2022.

• The leading Respiratory Syncytial Virus Companies include Bavarian Nordic, GlaxoSmithKline, Janssen, Sanofi, AstraZeneca, Moderna, ReViral, Pfizer, and Others

• Promising Respiratory Syncytial Virus Pipeline Therapies include Nirsevimab, AK0529, Palivizumab, Suptavumab 30 mg/kg, and others

Explore more information about the Latest Drugs Launch, New Breakthroughs of Drugs or Therapies Approaches, Treatment Practices, and Forecasted Epidemiology @ Respiratory Syncytial Virus Market Size- https://www.delveinsight.com/report-store/respiratory-syncytial-virus-rsv-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Respiratory Syncytial Virus Overview

Respiratory Syncytial Virus is a common respiratory virus that infects the nose, throat, lungs, and breathing passages. Respiratory Syncytial Virus belongs to the genus Orthopneumovirus within the family Pneumoviridae and order Mononegavirales. Members of this genus include human Respiratory Syncytial Virus, bovine Respiratory Syncytial Virus, and murine pneumonia virus.

Respiratory Syncytial Virus Epidemiology Segmentation in the 7MM
• Respiratory Syncytial Virus Patient Pool
• Respiratory Syncytial Virus Forecasted Trends

Download the report to understand which factors are driving Respiratory Syncytial Virus epidemiology trends @ Respiratory Syncytial Virus Epidemiological Insights- https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Respiratory Syncytial Virus Marketed Drugs

• SYNAGIS (palivizumab): Swedish Orphan Biovitrum AB (SOBI):
Palivizumab is a humanized monoclonal antibody (IgG1?) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of Respiratory Syncytial Virus. SYNAGIS is supplied as a sterile, preservative-free liquid solution at 100 mg per mL to be administered by intramuscular injection. In June 1998, SYNAGIS was approved to prevent serious lower respiratory tract disease caused by Respiratory Syncytial Virus in pediatric patients in the US.

Respiratory Syncytial Virus Emerging Drugs

Respiratory Syncytial ViruspreF (PF-06928316): Pfizer
Pfizer's investigational Respiratory Syncytial Virus vaccine candidate, Respiratory Syncytial ViruspreF, builds on foundational basic science discoveries, including those made at the National Institutes of Health (NIH), which detailed the crystal structure of prefusion F, a key form of the viral fusion protein (F) that Respiratory Syncytial Virus uses to attack human cells. In March 2022, Pfizer announced that its Respiratory Syncytial Virus vaccine candidate, PF-06928316 or Respiratory Syncytial ViruspreF, received BTD from the US FDA to prevent lower respiratory tract disease caused by Respiratory Syncytial Virus in individuals 60 years or older.

Respiratory Syncytial VirusPreF3 (GSK3844766A) Vaccine: GlaxoSmithKline
GSK3844766A contains a recombinant subunit pre-fusion Respiratory Syncytial Virus antigen combined with GSK's proprietary AS01 adjuvant, which is also used in the company's shingles vaccine. The drug has accepted regulatory submissions in Europe and Japan for older adults aged 60+. The Regulatory decision in the US is expected in the first half of 2023. US FDA has set a Prescription Drug User Fee Act action date of May 2023.

mRNA-1345: Moderna
The mRNA-1345 vaccine is a messenger RNA (mRNA) vaccine. This mRNA is entirely made in a laboratory and instructs the body to build small pieces of proteins. Moderna's mRNA-1345 Respiratory Syncytial Virus vaccine candidate encodes for a prefusion F glycoprotein, eliciting a superior neutralizing antibody response. In August 2021, Moderna received the FDA's FTD for the Respiratory Syncytial Virus vaccine (mRNA-1345) in adults older than 60.

Respiratory Syncytial Virus Market Outlook

While understanding Respiratory Syncytial Virus pathogenesis and viral biology has increased over time, prevention of the virus is still lacking, often with severe disease burdens. Treatment for Respiratory Syncytial Virus infection is currently limited to supportive care and prophylactic antibody use. It may include hydration, supplemental oxygen, suctioning of airways, and mechanical ventilation when needed.

Learn more about the FDA-approved drugs for Respiratory Syncytial Virus @ Respiratory Syncytial Virus Market Drivers and Barriers- https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Respiratory Syncytial Virus Market Report

• Coverage- 7MM
• Study Period- 2019-2032
• Respiratory Syncytial Virus Companies- Bavarian Nordic, GlaxoSmithKline, Janssen, Sanofi, AstraZeneca, Moderna, ReViral, Pfizer, and Others
• Respiratory Syncytial Virus Pipeline Therapies- Nirsevimab, AK0529, Palivizumab, Suptavumab 30 mg/kg, and others
• Respiratory Syncytial Virus Market Dynamics: Respiratory Syncytial Virus Market Drivers and Barriers

Discover more about Respiratory Syncytial Virus Drugs in development @ Respiratory Syncytial Virus Emerging Drugs and Companies- https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Report Introduction
3. Respiratory Syncytial Virus (RSV) Market Overview at a Glance
4. Executive Summary of Respiratory Syncytial Virus (RSV)
5. Key Events
6. Disease Background and Overview
7. Treatment and Management
8. Methodology
9. Epidemiology and Patient Population
10. Patient Journey
11. Marketed Products
12. Emerging Therapies
13. Respiratory Syncytial Virus (RSV) Seven Major Market Analysis
14. Market Access and Reimbursement
15. RSV Reimbursement
16. KOL Views
17. Unmet Needs
18. SWOT Analysis
19. Appendix
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

Got Queries? Reach out for more information about the Patient Population, Treatment Algorithm, Unmet Needs, and Emerging Drugs of the report @ Respiratory Syncytial Virus Market Dynamics- https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.